EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Permissive Cardiotoxicity: An Evolving Paradigm

David L Madnick iD, Elizabeth Hutchins iD, Ashley F Stein-Merlob iD, Eric H Yang iD

Journal of the American Heart Association · 20.10.2026 · 15 (20)

DOI: 10.1161/jaha.126.051633 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 20.10.2026. Verfasst von David L Madnick und 3 weiteren Autor:innen. Beteiligte Einrichtung: UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine David Geffen School of Medicine at UCLA Los Angeles CA USA. Hauptthemen laut MEDLINE: Cardiotoxicity, Antineoplastic Agents, Neoplasms, Heart Diseases. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Permissive cardiotoxicity is an evolving clinical practice pattern that balances the management of cancer treatment‐associated cardiotoxicities with the risk of interrupting lifesaving or life‐extending cancer treatments. This paradigm shift has been catalyzed by advancements in the diagnostic and therapeutic tools available to treating clinicians, as well as a recognition of the consequences of withholding or delaying cancer therapy. Permissive cardiotoxicity has become a central tenet in the practice of cardio‐oncologists; however, recognition and confidence in managing cardiotoxicity is also crucial for the general cardiologist and oncologist due to the growing population of patients with cancer. This review aims to (1) highlight the philosophy of permissive cardiotoxicity, (2) provide a framework for risk stratification of cardiovascular toxicities, (3) describe systems of care considerations for successful implementation of permissive cardiotoxicity, and (4) review the existing literature and guideline recommendations for specific cardiovascular toxicity mitigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiotoxicityAntineoplastic AgentsNeoplasmsHeart DiseasesHumansRisk AssessmentRisk Factors

Stichwörter der Autor:innen

cardioprotective therapiescardio‐oncologychemotherapy‐induced cardiac injurypermissive cardiotoxicity

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine David Geffen School of Medicine at UCLA Los Angeles CA USA.

ORCID-Profile: David L Madnick, Elizabeth Hutchins, Ashley F Stein-Merlob, Eric H Yang

Förderung

  • NCATS NIH HHS

Zitieren

APA

Madnick, D. L., Hutchins, E., Stein-Merlob, A. F., & Yang, E. H. (2026). Permissive Cardiotoxicity: An Evolving Paradigm. Journal of the American Heart Association, 15(20). https://doi.org/10.1161/jaha.126.051633

Vancouver

Madnick DL, Hutchins E, Stein-Merlob AF, Yang EH. Permissive Cardiotoxicity: An Evolving Paradigm. Journal of the American Heart Association. 2026;15(20). doi:10.1161/jaha.126.051633

BibTeX
@article{Madnick2026,
  author = {Madnick, David L and Hutchins, Elizabeth and Stein-Merlob, Ashley F and Yang, Eric H},
  title = {Permissive Cardiotoxicity: An Evolving Paradigm},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {20},
  doi = {10.1161/jaha.126.051633}
}
Kostenlos starten →